TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05698615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chess training
Description: The chess training, which takes place as a measure for CRT with the children and adolescents, is carried out by the concept of the Munich Chess Academy. The concept applied here, Chess according to the King's Plan, represents a holistic concept. Especially prepared for children and adolescents, theoretical aspects are illustrated in games and exercises.
Study: NCT05922228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neural flossing with proprioceptive neuromuscular facilitation
Description: neural flossing technique for 5minutes, 10 repetitions×1 set, 3 days/week contract relax technique of proprioceptive neuromuscular facilitation for 5 minutes, 10 repetitions ×1 set, 3 days/week total of 15 sessions were given as 3 sessions/week up to 5 weeks, each session consisting of 10 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neural flossing without proprioceptive neuromuscular facilitation
Description: neural flossing technique for 5minutes, 10 repetitions×1 set, 3 days/week total of 15 sessions were given as 3 sessions/week up to 5 weeks, each session consisting of 5 minutes
Study: NCT02919163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by incandescent white light bulbs and color filters.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by incandescent white light bulbs and color filters.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by incandescent white light bulbs and color filters.
Study: NCT06388135

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: nab-paclitaxel，Cisplatin
Description: nab-paclitaxel，Cisplatin
Study: NCT05376995

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Graston technique
Description: Graston technique among patient of knee osteoarthritis

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: muscle energy technique
Description: muscle energy technique among patient of knee osteoarthritis
Study: NCT05521646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality Improvement Collaborative
Description: Explore if a Quality Improvement Collaborative can increase the proportion of immigrant women who choose an effective postpartum contraceptive method
Study: NCT02919163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by incandescent white light bulbs and color filters.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by incandescent white light bulbs and color filters.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by incandescent white light bulbs and color filters.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by incandescent white light bulbs and color filters.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by incandescent white light bulbs and color filters.
Study: NCT05951543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plyometric exercises
Description: Experimental group will be given baseline exercises along with plyometric exercises such as Vertical jump, run and jump, drop jump (jump height between 40 and 50 cm) drop jump and horizontal jump with same height from 3rd week.particepents perform exercises carrying medicine balls. Participants will place their hands on the wall and performed foot stretches with the feet apart, 30 to 50 cm from the wall. Side row, biceps stretch and frontal row. Throwing and receiving, with a distance between 3 to 4 m.

Intervention type: OTHER
Group type: OTHER
Intervention: dynamic balance group control group
Description: Control group will be given with the standard physical therapy intervention that includes progressive resistance training that will be performed using weights, two sets of 10 repetitions will be given for each muscle group, resistance will be increased by ½ Kg as children are able to complete without undue stresses); balance exercises (stand on a balance board, one-leg stance, heal-to-toes stance, walking on balance board, walking on a balance beam, walking on a line, and walking on the inclined surface); flexibility exercises
Study: NCT06169995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate
Description: bolus dose: 5mg，IV supplemental dose: 2.5mg，IV
Study: NCT06044233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI-1558
Description: STI-1558 test preparation and reference preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI-1558
Description: STI-1558 test preparation and reference preparation
Study: NCT06402786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kitea ICP Sensor
Description: Kitea ICP Sensor placed in brain during shunt surgery.
Study: NCT04583124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ATENTO-B
Description: Patients will perform therapeutic exercise and vagal activation techniques before medical treatment and will follow the usual care after medical treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ATENTO-T
Description: Patients will perform therapeutic exercise and vagal activation techniques throughout medical treatment and will follow the usual care after medical treatment.
Study: NCT05004519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injection [Precedex]
Description: dexmedetomidine or remifentanil during laparoscopic gastric bypass

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: dexmedetomidine or remifentanil during laparoscopic gastric bypass
Study: NCT05452109

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction
Description: Blood flow restriction with low load (30-50% 1RM) for 2 sessions in a week for 6 weeks during classical training will be applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical Training Alone
Description: Classical training same as Group 1with moderate to high load (70-90% 1RM) for 2 sessions in a week for 6 weeks will be applied without blood restriction.
Study: NCT05296746

Intervention type: DRUG
Group type: OTHER
Intervention: Ribociclib (neoadjuvant)
Description: Ribociclib 600 mg/day + letrozole during neoadjuvant phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib (neoadjuvant)
Description: Ribociclib 600 mg/day + letrozole during neoadjuvant phase.
Study: NCT05387798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD011
Description: Cannabidiol Oral Solution (containing synthetic cannabidiol)
Study: NCT05296746

Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy (adjuvant)
Description: Adjuvant chemotherapy. 3 regimens are permitted.

Intervention type: DRUG
Group type: OTHER
Intervention: Ribociclib (adjuvant)
Description: Ribociclib 400 mg/day + letrozole (or other aromatase inhibitor) during adjuvant phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib (adjuvant)
Description: Ribociclib 400 mg/day + letrozole (or other aromatase inhibitor) during adjuvant phase.
Study: NCT06260449

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical removal
Description: Removal of the granuloma

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical removal
Description: Removal of the granuloma
Study: NCT06510179

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrushing
Description: Patients brush their teeth using the technique instructed to them using the toothbrush provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toothbrushing
Description: Patients brush their teeth using the technique instructed to them using the toothbrush provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toothbrushing
Description: Patients brush their teeth using the technique instructed to them using the toothbrush provided.
Study: NCT05274516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2261 tablet、placebo
Description: HRS-2261 oral tablet, oral, single dose. Matching placebo to HRS-2261, oral, single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2261 tablet、placebo
Description: HRS-2261 oral tablet, oral, BID. Matching placebo to HRS-2261, oral, BID.
Study: NCT05068505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community health worker delivered multicomponent intervention
Description: The multi-component intervention will be centered on monthly household visits by trained CHWs for a period of seven months in a rural setting in Nakaseke, Uganda, consisting of the following; (1) blood pressure and sugar monitoring; (2) BMI monitoring; (3) cardiovascular disease risk assessment; (4) Using checklists to guide monitoring and referral to clinics; (5) healthy lifestyle counselling and education. During home visits, CHWs will remind patients of follow-up visits. We will measure blood pressure at baseline and 3-monthly for the entire cohort. We will conduct individual-level mixed effects analyses of study data, adjusting for time and clustering by patient and community.~We will conduct an interim analysis at 3 months to assess differences between groups. If a statistically significant difference is detected the intervention will be applied across the remaining clusters
Study: NCT06318247

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: site preservation
Description: Tooth extraction of third molars with site preservation using bio-oss (0.5g, Small granule) and bio-guide (25\*25mm size). The bone graft material used in the surgical procedure was provided by Geistlich Pharma AG.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: site preservation
Description: Tooth extraction of third molars with site preservation using bio-oss (0.5g, Small granule) and bio-guide (25\*25mm size). The bone graft material used in the surgical procedure was provided by Geistlich Pharma AG.
Study: NCT05092113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: a compound glutamine capsule/a compound glutamine capsule simulated placebo
Description: A compound glutamine capsule/a compound glutamine capsule simulated placebo was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: a compound glutamine capsule/a compound glutamine capsule simulated placebo
Description: A compound glutamine capsule/a compound glutamine capsule simulated placebo was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
Study: NCT04745312

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visible light
Description: Ambient room lighting will be supplemented with additional light from a task lamp.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visible light
Description: Ambient room lighting will be supplemented with additional light from a task lamp.
Study: NCT05474989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSD
Description: Moderate to high dose LSD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active placebo
Description: Low dose LSD
Study: NCT02067533

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: soft tissue repair in flexion position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: soft tissue repair in extension position
Study: NCT04725539

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hypoxic exposure
Description: Administration of different hypoxic doses.~Intermittent hypoxia:~days 1-5 duration of breathing periods 5\*3min (FiO2 14-21%) days 8-12 duration of breathing periods 4\*4min (FiO2 = 12%) and 3\*3 min (FiO2 = 21%) days 15-19 duration of breathing periods 5\*5min (FiO2 = 10%) and 4\*3 min (FiO2 = 21%)~one night at 1900m

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hypoxic exposure
Description: Administration of different hypoxic doses.~Intermittent hypoxia:~days 1-5 duration of breathing periods 5\*3min (FiO2 14-21%) days 8-12 duration of breathing periods 4\*4min (FiO2 = 12%) and 3\*3 min (FiO2 = 21%) days 15-19 duration of breathing periods 5\*5min (FiO2 = 10%) and 4\*3 min (FiO2 = 21%)~one night at 1900m
Study: NCT03822338

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum preconditioning
Description: Pneumoperitoneum preconditioning consists of three cycles of 5 min insufflation and 5 min desufflation, after complete anesthesia and successfully implanting the veress. This process will be induced by pneumoperitoneum machine, and the utilized gas will be carbon dioxide to maintain the intra-abdominal pressure at 15 mmHg. The whole duration will last 30 min.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-Pneumoperitoneum preconditioning
Description: Sham-Pneumoperitoneum preconditioning consists of three cycles without insufﬂation and subsequent desufﬂation. The whole duration will also last 30 min.
Study: NCT03936478

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRIdian Radiation Treatment Unit
Description: partial breast irradiation using 3 x 8.2 Gy to the lumpectomy cavity with a 3mm planning tumor volume (PTV) margin
Study: NCT05503979

Intervention type: DRUG
Intervention: Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa]
Description: 1 tab every 24 hrs for 12 weeks
Study: NCT05537610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CDT
Description: In this condition, the clinician will alternate sessions with reinforcement for the alternative response and sessions without reinforcement for the alternative response during extinction treatment of problem behavior. According to RaC2, alternating periods of reinforcer availability and unavailability for the alternative response will teach the participant that the alternative response alone produces reinforcement but not always. The investigators predict that resurgence of problem behavior will lower, shorter lasting, and with fewer participants experiencing resurgence than those in the control group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This condition emulates a traditional approach to treatment in which the clinician does not alternate sessions with reinforcement for the alternative response and sessions without reinforcement for the alternative response during extinction treatment of problem behavior. The investigators predict that resurgence of problem behavior will higher, longer lasting, and with more participants experiencing resurgence than those in the CDT group.
Study: NCT05730101

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral treatment (CBT)
Description: In the first individual session (CBT1), together with the therapist, participants develop a behavioral and conditional model of their procrastination behavior. In the next 2 group sessions (CBT2 and CBT3), participants receive psychoeducation on procrastination. The focus is on learning the method of starting on time. In the third group session (CBT4), participants identify key procrastination-promoting thoughts and are supported to develop alternative thoughts; deepened in the second individual session (CBT5). In the next 2 group sessions (CBT 6 and CBT7), participants are informed about action planning with focus on learning to plan realistically. The last group session is a concluding session: Experiences with the methods learned and an outlook on further steps and goals are discussed. At the end of both individual sessions (CBT1 and CBT5), participants receive a link to an online survey to rate their treatment expectations (treatment expectation 1 and 2).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Imaginary pill treatment (IP)
Description: In the first session (IP1), participants will be asked about the nature of their procrastination behavior and receive a procedure to take an imaginary pill following a rationale of 5 steps. In the second IP session (IP2), experiences with taking the IP are discussed and the procedure of taking the IP is adapted according to previous experiences and current needs. The rationale of the second session encompasses the same five steps with small modifications: 1) discussing IP sensitive problem and adapting it if necessary, 2) building trust/belief/reality of the IP, 3) discussing the personally meaningful IP and adapting it if necessary, 4) taking the IP, 5) adapting the procedure for self-administering the IP in real life on daily basis if necessary and building adherence. At the end of both sessions, participants receive a link to an online survey to rate their treatment expectations (treatment expectation 1 and 2).
Study: NCT05676801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: PDT with methyl aminolevulinate (MAL) as the prodrug for the photosensitizer Pp IX
Study: NCT02846857

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 15-week intervention with sensor-augmented pump
Description: A sensor will be inserted on the day before the start of the intervention by the participant. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 15 weeks. Participants will have been previously shown how to use the study insulin pump.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 15-week intervention with single-hormone closed-loop
Description: A sensor will be inserted on the day before the start of the intervention by the participant. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 15 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 15-week intervention with dual-hormone closed-loop
Description: A sensor will be inserted on the day before the start of the intervention by the participant. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 15 weeks. Participants will have to reconstitute glucagon everyday.
Study: NCT06353048

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fixation of tibial plateau fractures
Description: fixation of tibial plateau fractures by screws only versus plate and screws

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fixation of tibial plateau fractures
Description: fixation of tibial plateau fractures by screws only versus plate and screws
Study: NCT04903574

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NEAT!2 sedentary behavior app
Description: This is a smartphone app that reminds you to stand up if you've been sitting for at least 30 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pregnancy smartphone app
Description: This is a commercially available general pregnancy smartphone app
Study: NCT04941430

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging using 7 Tesla MRI
Description: Undergo 7T MRI
Study: NCT06216041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM-H014
Description: SAD and MAD adopt sentinel method which 2 healthy subjects first will receive IMM-H014, and if are evaluated to be tolerable, the remaining 8 subjects will be randomly assigned to receive IMM-H014 and placebo in a ratio of 3:1(10 in per experimental Cohort).
Study: NCT02846857

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump
Description: MiniMed® Paradigm® Veo™, Medtronic

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump
Description: MiniMed® Paradigm® Veo™, Medtronic

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump
Description: MiniMed® Paradigm® Veo™, Medtronic

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring system
Description: Enlite sensor®, Medtronic
Study: NCT02846857

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring system
Description: Enlite sensor®, Medtronic

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring system
Description: Enlite sensor®, Medtronic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.